High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma.

Haematologica

Volumn 92, Issue 12, 2007, Pages

  van der Spek, E ^a   Bloem, A C ^a   Sinnige, H A ^a   Lokhorst, H M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; DOXORUBICIN; SIMVASTATIN; UNCLASSIFIED DRUG; VAD PROTOCOL; VINCRISTINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I AS TOPIC; DEXAMETHASONE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; SIMVASTATIN; VINCRISTINE;

EID: 38949101479     PISSN: None     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.12071     Document Type: Article

References (0)